Follow the ARTRYA LIMITED share price and the full insider trade history of the company, a listed issuer based in Australia. Shares are quoted on the AU market, under the oversight of ASX. Market capitalisation: €786.8m. The latest transaction was reported on 19 August 2026 (Other). Among the most active insiders: Bernie Ridgeway. Every trade is accessible without an account.
Analysts rate ARTRYA LIMITED Strong Buy (bullish), based on 3 analysts. Average price target: A$5.96.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
ARTRYA LIMITED is a company listed on the XASX, focused on developing technological solutions for cardiac health. It aims to improve clinical outcomes through digital innovation.